Linical is a public, midsized CRO headquartered in Japan with a significant presence across North America, Europe, and Asia-Pacific. Linical provides the full spectrum of drug development services from early stage to large-scale, multinational studies. Our areas of expertise include Phase I-IV oncology, vaccine, infectious disease, CNS and general medicine.
Linical was established in June 2005 by a group of professionals who were engaged in new drug development at a major Japanese pharmaceutical company. Ever since, in accordance with our philosophy of contributing to new drug development and promoting the well-being of patients, we have supported the clinical development efforts of pharmaceutical companies, focusing mainly on areas for which new drug development is sorely needed. Given the increasing internationalization of large scale pharmaceutical product development, Linical has actively expanded its activities around the world, to become the first Japanese Headquartered Global CRO (Contract Research Organization) capable of delivering a one-stop service for large-scale, global projects.
As part of that growth, in 2018, Linical and Accelovance merged to create a market-leading, midsized, global CRO. In 2020, the company streamlined its regional naming structure as a next step in the organization’s evolution. Linical's North American entity, previously known as Linical Accelovance America, is now doing business as Linical Americas. The name shift better aligns the organization’s North American operations under the unified Linical umbrella, as well as signals the company’s plans for further expansion within North and South America.
Linical is the ideal partner for drug developers looking to expand their program into new markets, combining strong business and operational perspective with clinical and medical expertise. We offer a personalized, hands-on service approach across a variety of therapeutic areas and in all phases of development.
Linical is an award winning CRO, and has been honored as a Best CRO ViE Award nominee by industry leaders 11 consecutive years, after being evaluated against global CROs for quality of services, performance, client satisfaction, Sponsor relationships, and the overall value brought to study Sponsors. Additionally, in 2020, Linical was named a winner of the 2020 CRO Leadership Award for Overall Compatibility servicing a combination of both large and small pharma and biotech clientele. Presented by Life Science Leader and Clinical Leader, the Awards evaluated over 60 contract research organizations on more than 20 performance metrics in ISR’s annual CRO Quality Benchmarking survey.
At Linical , patients are of the utmost importance to us, so we do all we can to improve their experience and impact the future of health care around the world. Our priority is building relationships with our clients, so we can fully understand their needs. We give each of our projects thoughtful care and attention, because it is our goal to deliver innovative solutions for even the most difficult industry challenges.
We offer the same reach and experience as larger CROs, but maintain the personal, attentive service our clients expect. We do this by strategically growing our business, maintaining the most talented workforce available and approaching each project with care.
Linical has a reputation as the CRO that cares; not only about the success of clinical research programs, but also about improving patient care. Our customers benefit from an organization whose values are centered around strength as a unit, and a mission and vision focused on quality, success, innovation and communication.
The Linical logo expresses our passion to pursue happiness of patients through our business activities.
- Blue: integrity and honesty
- Red: unending enthusiasm
- Yellow: continuing spirit of inquiry